The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target is a research paper published in Life (2022). On theSindex it has a DataRank of 0. It has been cited 56 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA227993
National Institutes of Health
Grant: CA229910
NCI NIH HHS
Grant: R01 CA227993
NCI NIH HHS
Grant: R01 CA229910
FWCI
6.27
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease